Pseudomonas Aeruginosa Treatment

Specialty Adblock test (Why?)

Abstract Use of hijab can influence the scalp's condition, including its microbiome. To date there has been no study comparing scalp microbiome in women wearing hijab to that in women not wearing hijab. This was a cross-sectional study conducted from August 2019 to April 2021. Healthy women aged 18 years old or older who had not undergone menopause were recruited. Those in the hijab group should wear hijab minimum 8 h a day for at least 5 years. After wash-out period, the sample was collected from the subject's scalp. Next Generation Sequencing (NGS) was performed with primer V3-V4 region of 16S rRNA and ITS1 DNA for bacteria and fungi, respectively. Alpha diversity and beta diversity were identified, along with functional analysis. Actinobacteria and Ascomycota were the most dominant phyla on the scalp. S. capitis was more prominent in the hijab group while S. cohnii was more prominent in non-hijab group. Additionally, M. restricta was more common

Infections, particularly sepsis, are responsible for 10% of maternal deaths shortly before, during and after childbirth, putting such infections in the top five causes of maternal mortality worldwide. "A single dose of the antibiotic azithromycin decreased sepsis and death by half in women in labor," said researcher Dr. William A. Petri Jr., of the University of Virginia School of Medicine's Division of Infectious Diseases and International Health. "The simplicity of this intervention should allow its institution around the globe to protect mothers during childbirth." Petri is part of the Azithromycin Prophylaxis in Labor Use Study (A-PLUS) Trial Group, an international coalition of researchers that set out to determine if giving the antibiotic during childbirth would benefit either mothers or their children. More than 29,000 women in low- and middle-income countries volunteered to take part in the randomized trial; half were given azithromycin and half

[unable to retrieve full-text content] A Probiotic May Equal Antibiotics in Fighting Staph Infection    U.S. News & World Report

International Group B Strep Awareness Month – July, 2023 Key Facts According to the CDC: In the United States, GBS bacteria are a leading cause of meningitis and bloodstream infections in a newborn's first three months of life. About 1 in 4 pregnant women carries GBS bacteria in their body. Group B Streptococcus (GBS) bacteria does not spread through food, water, or anything that people might have come into contact with. How people get these bacteria or spread them to others is generally unknown. However, experts know that pregnant women can pass the bacteria to their babies during delivery. The two best ways to prevent GBS disease during the first week of a newborn's life are: Testing pregnant women for GBS bacteria Giving antibiotics, during labor, to women at increased risk International Group B Strep Awareness Month Oh, baby! July is Group B Strep International Awareness Month. A month used to promote the awareness and prevention of grou

Specialty Adblock test (Why?)

Specialty Adblock test (Why?)

Rotavirus-associated hospitalization was significantly associated with subsequent autoimmune disease during childhood, according to a large population-based cohort study from South Korea. Over a mean follow-up of 12 years, children who were hospitalized for rotavirus had a significantly greater risk for autoimmune disease compared with those who weren't (HR 1.24, 95% CI 1.19-1.28), reported Man Yong Han, MD, of CHA Bundang Medical Center at the CHA University School of Medicine in Seongnam, and colleagues. In a multivariable stratified analysis using more stringent definitions for exposure and outcomes, rotavirus-associated hospitalization was also linked with an increased risk of subsequent autoimmune disease (HR 1.22, 95% CI 1.16-1.28), they noted in JAMA Network Open . Furthermore, in a sensitivity analysis, they found that the association between rotavirus hospitalization and autoimmune disease was stronger for those with two or more autoimmune syndromes (HR 1.51, 95% CI

CINCINNATI , July 25, 2023 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) has cleared Premier ® HpSA ® FLEX™ for the diagnosis of H. pylori in both preserved and unpreserved stools. Premier HpSA Flex joins the extensive Meridian H. pylori portfolio of products that includes BreathID ® (urea breath test for H. pylori ), Curian ® HpSA (fluorescent immuno analyzer antigen test), and ImmunoCard ® Stat! HpSA (rapid colorimetric antigen test). Continue Reading Meridian strives to continuously improve existing products. The Premier HpSA FLEX workflow improvement recently cleared by FDA allows clinicians to use preserved stools in Cary-Blair and C&S in addition to fresh or frozen unpreserved samples. Meridian's Premier HpSA FLEX test is a non-invasive enzyme immunoassay used to qualit

ASHEVILLE, North Carolina — Epidermolysis bullosa (EB), a heterogeneous congenital condition of skin fragility, received its first FDA-approved gene therapy only a few months ago, but accelerated progress across multiple treatment strategies predicts additional important and perhaps dramatic further progress, according to a prominent EB researcher. Not only are recent developments in EB "exciting," the progress on multiple fronts for control of disease or its symptoms suggests "we are on the cusp of a new era," Jemima Mellerio, BSc, MD, a consultant dermatologist, St. John's Institute of Dermatology, London, England, said at the annual meeting of the Society for Pediatric Dermatology. Published clinical studies of cell therapies and gene therapies date back at least 15 years, according to a review by Mellerio on why developments are starting to move so quickly. The difference now is that many obstacles to routine use of these option

A systematic literature review published in JAMA Dermatology provides proof that biosimilar drugs are safe and effective in treating psoriasis. An analysis of clinical studies that compared approved biological drugs (so-called originator drugs) with their biosimilar counterparts has failed to find clinically meaningful differences between the two with respect to efficacy and adverse events. This evidence could be used to promote the use of biosimilars in dermatology and in medicine generally. Yet, despite their potential advantages ― namely, easier access to innovative therapies and consistent economic savings ― doctors and patients alike have been slow to accept biosimilars as a treatment option. Brand Name Appeal Resistance to biosimilars is a problem in Italy, although the country is currently seeing a reversal of this trend. "After a period of reluctance, the use of biosimilars has gained quite a foothold. This includes new initiatives i

Adam RD. Biology of Giardia lamblia . Clin Microbiol Rev. 2001;14:447–75. Article  CAS  PubMed  PubMed Central  Google Scholar  Solaymani-Mohammadi S, Singer SM. Giardia duodenalis : the double-edged sword of immune responses in giardiasis. Exp Parasitol. 2010;126:292–7. Article  CAS  PubMed  PubMed Central  Google Scholar  Solaymani-Mohammadi S. Mucosal defense against Giardia at the intestinal epithelial cell interface. Front Immunol. 2022;13:817468. https://doi.org/10.3389/fimmu.2022.817468. Article  CAS  PubMed  PubMed Central  Google Scholar  Yoder JS, Gargano JW, Wallace RM, Beach MJ. Giardiasis surveillance-United States, 2009–2010. MMWR Surveill Summ. 2012;6:13–23.